7Baggers
 published on: 2025-11-14 17:50:20  newser.com Fri, 14 Nov 2025 23:50:20 GMT
 published on: 2025-11-13 17:41:50  newser.com Thu, 13 Nov 2025 23:41:50 GMT
 published on: 2025-11-13 05:42:30  newser.com Thu, 13 Nov 2025 11:42:30 GMT
 Nkarta (NKTX) Receives a Buy from H.C. Wainwright  The Globe and Mail Wed, 12 Nov 2025 22:16:30 GMT
 published on: 2025-11-12 02:36:29  newser.com Wed, 12 Nov 2025 08:36:29 GMT
 published on: 2025-11-11 20:36:52  newser.com Wed, 12 Nov 2025 02:36:52 GMT
 Nkarta price target lowered to $11 from $12 at Stifel  TipRanks Tue, 11 Nov 2025 12:47:15 GMT
 Nkarta Advances NKX019 Program Amid Financial Stability  TipRanks Tue, 11 Nov 2025 04:17:33 GMT
 Nkarta Q3 net loss $21.7 mln  MarketScreener Mon, 10 Nov 2025 21:15:19 GMT
 Nkarta reports Q3 EPS (29c), consensus (30c)  TipRanks Mon, 10 Nov 2025 21:07:17 GMT
 published on: 2025-11-09 06:08:33  newser.com Sun, 09 Nov 2025 12:08:33 GMT
 published on: 2025-11-05 21:47:08  newser.com Thu, 06 Nov 2025 03:47:08 GMT
 Is Nkarta (NASDAQ:NKTX) In A Good Position To Deliver On Growth Plans?  simplywall.st Sat, 01 Nov 2025 07:00:00 GMT
 nkarta shares face pressure ahead of quarterly earnings report ()  aktiencheck.de Sat, 01 Nov 2025 01:38:00 GMT
 nkarta (nktx) to release earnings on thursday  MarketBeat Thu, 30 Oct 2025 08:02:51 GMT
 Nkarta to Participate in November Investor Conferences  GlobeNewswire Thu, 30 Oct 2025 07:00:00 GMT

Nkarta, Inc
(NASDAQ:NKTX) 

NKTX stock logo

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific p...

Founded: 2015
CEO: Paul J. Hastings  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends